(NASDAQ: LQDA) Liquidia's forecast annual revenue growth rate of 70.17% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Liquidia's revenue in 2026 is $158,320,000.On average, 10 Wall Street analysts forecast LQDA's revenue for 2026 to be $43,030,681,402, with the lowest LQDA revenue forecast at $22,225,983,571, and the highest LQDA revenue forecast at $64,171,976,352. On average, 8 Wall Street analysts forecast LQDA's revenue for 2027 to be $54,838,896,032, with the lowest LQDA revenue forecast at $34,807,842,888, and the highest LQDA revenue forecast at $73,387,864,481.
In 2028, LQDA is forecast to generate $68,738,066,063 in revenue, with the lowest revenue forecast at $55,268,013,302 and the highest revenue forecast at $91,550,891,731.